tiprankstipranks
Trending News
More News >

Sichuan Kelun-Biotech Gains Approval for H Share Circulation

Story Highlights
Sichuan Kelun-Biotech Gains Approval for H Share Circulation

Confident Investing Starts Here:

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from the Hong Kong Stock Exchange for the full circulation of its H shares. This approval allows the conversion of 25,421,196 domestic shares into H shares, increasing the proportion of H shares in the company’s total share capital from 57.83% to 69.02%. This strategic move is expected to enhance the company’s market liquidity and potentially attract more international investors, reflecting positively on its market positioning.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in China, operating in the biopharmaceutical industry. The company focuses on the development and commercialization of biopharmaceutical products, with a market focus on both domestic and international stakeholders.

YTD Price Performance: 71.95%

Average Trading Volume: 517,801

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$59.19B

For an in-depth examination of 6990 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App